172 related articles for article (PubMed ID: 31807173)
1. Prognostic phenotypic classification for canine mammary tumors.
Varallo GR; Gelaleti GB; Maschio-Signorini LB; Moschetta MG; Lopes JR; De Nardi AB; Tinucci-Costa M; Rocha RM; De Campos Zuccari DAP
Oncol Lett; 2019 Dec; 18(6):6545-6553. PubMed ID: 31807173
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
[TBL] [Abstract][Full Text] [Related]
3. Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression.
Pinho SS; Matos AJ; Lopes C; Marcos NT; Carvalheira J; Reis CA; Gärtner F
BMC Cancer; 2007 Jul; 7():124. PubMed ID: 17617904
[TBL] [Abstract][Full Text] [Related]
4. HER-2, EGFR, Cox-2 and Ki67 expression in lymph node metastasis of canine mammary carcinomas: Association with clinical-pathological parameters and overall survival.
Araújo MR; Campos LC; Damasceno KA; Gamba CO; Ferreira E; Cassali GD
Res Vet Sci; 2016 Jun; 106():121-30. PubMed ID: 27234549
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K; Slembrouck L; Olbrecht S; Jongen L; Brouckaert O; Wildiers H; Floris G; Van Limbergen E; Weltens C; Smeets A; Paridaens R; Giobbie-Hurder A; Regan MM; Viale G; Thürlimann B; Vergote I; Christodoulou E; Van Calster B; Neven P
Oncologist; 2019 Feb; 24(2):165-171. PubMed ID: 30171067
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating CD4
Franzoni MS; Brandi A; de Oliveira Matos Prado JK; Elias F; Dalmolin F; de Faria Lainetti P; Prado MCM; Leis-Filho AF; Fonseca-Alves CE
Res Vet Sci; 2019 Oct; 126():29-36. PubMed ID: 31425936
[TBL] [Abstract][Full Text] [Related]
7. Molecular based subtyping of feline mammary carcinomas and clinicopathological characterization.
Soares M; Madeira S; Correia J; Peleteiro M; Cardoso F; Ferreira F
Breast; 2016 Jun; 27():44-51. PubMed ID: 27212699
[TBL] [Abstract][Full Text] [Related]
8. Identification of triple-negative and basal-like canine mammary carcinomas using four basal markers.
Kim NH; Lim HY; Im KS; Kim JH; Sur JH
J Comp Pathol; 2013 May; 148(4):298-306. PubMed ID: 23079102
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
[TBL] [Abstract][Full Text] [Related]
11. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
Recăreanu F; Simionescu C; Georgescu CV; Pirici E
Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of her-2/neu in malignant mammary tumors; translation of clinicopathological features from dog to human.
Muhammadnejad A; Keyhani E; Mortazavi P; Behjati F; Haghdoost IS
Asian Pac J Cancer Prev; 2012; 13(12):6415-21. PubMed ID: 23464468
[TBL] [Abstract][Full Text] [Related]
13. The investigation of transcriptional repression mediated by ZEB2 in canine invasive micropapillary carcinoma in mammary gland.
Gamba CO; Damasceno KA; Ferreira IC; Rodrigues MA; Gomes DA; Alves MR; Rocha RM; Lima AE; Ferreira E; Cassali GD
PLoS One; 2019; 14(1):e0209497. PubMed ID: 30645591
[TBL] [Abstract][Full Text] [Related]
14. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
[TBL] [Abstract][Full Text] [Related]
15. Significance and prognosis of epithelial-cadherin expression in invasive breast carcinoma.
Yang L; Wang XW; Zhu LP; Wang HL; Wang B; Zhao Q; Wang XY
Oncol Lett; 2018 Aug; 16(2):1659-1665. PubMed ID: 30008850
[TBL] [Abstract][Full Text] [Related]
16. CD44 and CD24 Expression and Prognostic Significance in Canine Mammary Tumors.
Rogez B; Pascal Q; Bobillier A; Machuron F; Lagadec C; Tierny D; Le Bourhis X; Chopin V
Vet Pathol; 2019 May; 56(3):377-388. PubMed ID: 30558511
[TBL] [Abstract][Full Text] [Related]
17. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
18. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
19. The Analysis of E-Cadherin, N-Cadherin, Vimentin, HER-2, CEA, CA15-3 and SF Expression in the Diagnosis of Canine Mammary Tumors.
Yu C; Zheng H; Liu X; Xie G
Animals (Basel); 2022 Nov; 12(21):. PubMed ID: 36359174
[TBL] [Abstract][Full Text] [Related]
20. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
